Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MF-1
- Development stage
- Unknown
- Lead developer
- University of Shizuoka
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MF-1 is a novel oral small molecule therapeutic candidate developed by the University of Shizuoka for the treatment of Parkinson's disease and other alpha-synucleinopathies. The agent is designed to inhibit the pathogenesis associated with alpha-synuclein, a protein whose aggregation and misfolding are central to the neurodegenerative process in Parkinson's disease. By targeting alpha-synuclein-related neurodegeneration, MF-1 aims to provide a disease-modifying treatment option for patients. It is currently undergoing Phase I clinical evaluation (MF1-FIH) to assess its safety, tolerability, and pharmacokinetics in healthy volunteers and patients with idiopathic Parkinson's disease.
02
Targets
SNCA (Alpha-synuclein)
Beyond the preview
Go deeper on MF-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MF-1.